Bojan Hrpka, DO
Family Medicine · Kalamazoo, MINPI 1437479433
Payments from drug & device makers
Across 85 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$183
- GSK$104
- AstraZeneca$103
- Amgen$96
- Abbott$94
- Merck$89
- plus $991 from 23 others
What the payments were for
- Food & beverage$1,660100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $183 |
| GSK | 6 | $104 |
| AstraZeneca | 7 | $103 |
| Amgen(2 entities) | 5 | $96 |
| Abbott | 4 | $94 |
| Merck | 4 | $89 |
| Pfizer | 5 | $85 |
| Dexcom, Inc. | 3 | $70 |
| Viiv Healthcare Company | 4 | $68 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Boehringer Ingelheim | 3 | $68 |
| Novartis | 3 | $61 |
| Exact Sciences | 3 | $56 |
| Astellas Pharma US Inc | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Lilly USA, LLC | 3 | $47 |
| Johnson & Johnson | 3 | $45 |
| Inspire Medical Systems, Inc. | 1 | $41 |
| AbbVie | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Bayer | 2 | $27 |
| Antares Pharma, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Biomarin Pharmaceutical Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Gilead | 1 | $13 |
How this compares
$1,660 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $145,202 |
| TrulicityDulaglutide | 65 | $83,802 |
| MounjaroTirzepatide | 63 | $79,754 |
| JardianceEmpagliflozin | 69 | $77,047 |
| EliquisApixaban | 61 | $74,345 |
| FarxigaDapagliflozin Propanediol | 18 | $13,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,401 |
| Repatha SureclickEvolocumab | 17 | $12,247 |
| XareltoRivaroxaban | 11 | $11,758 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,512 |
| Atorvastatin Calcium | 666 | $10,410 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,151 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $5,589 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $4,759 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $47 | $163,556128 claims |
| Novo NordiskOzempic | $183 | $145,202116 claims |
| Boehringer IngelheimJardiance | $68 | $77,04769 claims |
| PfizerEliquis | $85 | $74,34561 claims |
| AstraZenecaFarxiga, Symbicort | $103 | $18,46230 claims |
| GSKTrelegy Ellipta | $104 | $12,40120 claims |
| Johnson & JohnsonXarelto | $45 | $11,75811 claims |
| AbbVieSynthroid | $40 | $1,60620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Kalamazoo
- Theresa KordishKalamazoo$148K
- Eric HouchinKalamazoo$59K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.